DCAT

The CDMO landscape is shifting toward long-term strategic partnerships as drug modalities grow more complex and supply chain pressures mount. Noritsugu Fujita, Division President of Pharmaceutical Solutions Division at Terumo, explains how an integrated, single-source model for parenteral drug development aims to streamline the path to a patient-ready product.

Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges.

Joerg Ahlgrimm, CEO of SK pharmteco, outlines the company's strategic expansion into cell and gene therapy. He also details their commitment to global operational excellence and a culture of employee purpose.

Fernanda Onofre, PhD, explains how the dsm-firmenich ModulaSENSE® Bitter platform and the functional application of vitamins as excipients are revolutionizing drug palatability and performance.

Terry Novak, CEO of Benuvia, explores how pharmaceutical and biotech companies can mitigate development risks and accelerate speed-to-market by prioritizing technical alignment, robust project management, and early-stage collaboration with the right CDMO partner.

Olon is expanding global biologics and high-potency manufacturing capacity across four countries, with major ADC chain investments completing in 2026.

Pharma companies reveal capacity expansions and strategic pivots at DCAT Week 2026, signaling where supply chain investment is heading.

SGD Pharma and Prince launch sterile Type I glass nasal vials for the US market, targeting complex chronic conditions like Alzheimer's and Parkinson's.

How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by expanding capabilities and expertise.